title: Significant antitumor response of disseminated glioblastoma to bevacizumab resulting in long-term clinical remission in a patient with encephalocraniocutaneous lipomatosis: A case report.
abstract: The prognosis of recurrent and disseminated glioblastoma is very poor. Bevacizumab is an effective established therapy for recurrent glioblastoma following treatment with radiotherapy plus temozolomide. However, the efficacy of bevacizumab is limited to prolonging progression-free survival, without significant prolongation of the overall survival. We herein report a case of glioblastoma in a 32-year-old female patient with encephalocraniocutaneous lipomatosis (ECCL) that had disseminated following surgical resection and subsequent treatment with temozolomide and radiation therapy. The disseminated tumors disappeared completely after five courses of bevacizumab therapy. Surprisingly, the patient has remained in clinical remission for >2.5 years after dissemination by continuing this therapy. To the best of our knowledge, this is the first case of long-time clinical remission following glioblastoma dissemination and treatment with bevacizumab. In the present case, bevacizumab exerted an atypically strong antitumor effect against disseminated glioblastoma after multidisciplinary treatments had already been applied. Moreover, this is the first report of ECCL associated with a malignant brain tumor.
authors.affiliation: Department of Neurosurgery, Shizuoka City Shimizu Hospital, Shizuoka 424-8636, Japan.
authors.forename: Raita
authors.initials: R
authors.lastname: Fukaya
authors.affiliation: Department of Radiation Oncology, Shizuoka City Shimizu Hospital, Shizuoka 424-8636, Japan.
authors.forename: Masatoki
authors.initials: M
authors.lastname: Ozaki
authors.affiliation: Department of Neurosurgery, Keio University School of Medicine, Tokyo 160-8582, Japan.
authors.forename: Dai
authors.initials: D
authors.lastname: Kamamoto
authors.affiliation: Department of Neurosurgery, Keio University School of Medicine, Tokyo 160-8582, Japan.
authors.forename: Yukina
authors.initials: Y
authors.lastname: Tokuda
authors.affiliation: Department of Pathology, Keio University School of Medicine, Tokyo 160-8582, Japan.
authors.forename: Tokuhiro
authors.initials: T
authors.lastname: Kimura
authors.affiliation: Department of Neurosurgery, Shizuoka City Shimizu Hospital, Shizuoka 424-8636, Japan.
authors.forename: Masahito
authors.initials: M
authors.lastname: Fukuchi
authors.affiliation: Department of Neurosurgery, Shizuoka City Shimizu Hospital, Shizuoka 424-8636, Japan.
authors.forename: Koji
authors.initials: K
authors.lastname: Fujii
keywords: antitumor effect; bevacizumab; encephalocraniocutaneous lipomatosis; glioblastoma